Cagent Partners With 3comma for International Distribution of Serranator Family of PTA Devices

April 3, 2025—Cagent Vascular, Inc., the developer of serration technology for vessel dilation in endovascular interventions, announced its strategic partnership with 3comma Medical GmbH, a commercial services firm that specializes in bringing medical devices to international markets.

Under the collaboration, 3comma will serve as the exclusive international distributor in the European Union and the Middle East and North Africa markets for Cagent Vascular’s Serranator percutaneous transluminal angioplasty (PTA) serration balloon product family. 3comma will leverage its extensive network, industry expertise, and market insights to expedite the adoption of the Serranator family, stated Cagent Vascular.

According to the company, its serration balloon technology is designed to optimize vessel preparation, enhance arterial expansion, and address challenging lesion morphologies in peripheral artery disease and chronic limb-threatening ischemia.

The FDA-cleared Serranator and Serranator SL-Pro PTA serration balloon catheters use stainless steel microserration technology to create linear, interrupted scoring along the endoluminal surface. Serration occurs during slow-and-low balloon inflation. The international expansion builds upon the company’s commercial success and growth in the United States market, noted the company.